Transfer factor therapy in patients with subacute sclerosing panencephalitis.
Thirteen patients with subacute sclerosing panencephalitis (S.S.P.E.) at different stages of the disease were admitted for transfer factor treatment. The transfer factor was prepared from non-selected blood bank donors. The activity of the transfer factor was tested in patients with diseases other than S.S.P.E. and was found to be either clinically or immunologically active. Regardless of the number of transfer factor units applied a significant influence on the course of the disease was not apparant. The observed intermittant improvement of 3 patients was considered as spontaneous remission which is known to occur occasionally in S.S.P.E. The humoral and cellular immune response before and after transfer factor therapy did not reveal significant changes which could be correlated with transfer factor therapy.
D000293:Adolescent; D000914:Antibodies, Viral / Q000032:analysis; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D007070:Immunoglobulin A / Q000134:cerebrospinal fluid; D007074:Immunoglobulin G / Q000134:cerebrospinal fluid; D007075:Immunoglobulin M / Q000134:cerebrospinal fluid; D008297:Male; D008457:Measles / Q000150:complications; D008459:Measles virus / Q000276:immunology; D012882:Skin Tests; D013344:Subacute Sclerosing Panencephalitis / Q000276:immunology / Q000628:therapy*; D014165:Transfer Factor / Q000627:therapeutic use*
D000914:Antibodies, Viral; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D014165:Transfer Factor